02.02.2019, 00:25
Healthcare | Diagnostic Substances | USA
What happened with IDEXX Laboratories this quarter?
The companion animals business continues to be the star of the show. Sales in this division grew 10% on a reported basis.
Total instrument placements grew 8% to 3,957. The growth was led by its flagship Catalyst product, which posted instrument growth of 10%.
Recurring revenue from the companion animal group jumped 12%.
Reference laboratory diagnostic revenue grew 11% on an organic basis.
IDEXX's water business line grew 8% on an organic basis.
The company's livestock division declined 9% on a reported basis, but it grew 5% on an organic basis. Management said that African swine flu outbreaks in China were a major headwind for this business during the quarter.
Gross margin increased 90 basis points to 54.7%.
Operating margin expanded 170 basis points to 21%.
The huge jump in EPS is largely attributable to an elevated tax bill in the year-ago period. Adjusted EPS growth of 40% was still quite strong.
Zooming out to full-year results, here are the headline numbers for investors to see how the company did in 2018:
Revenue grew 12% to $2.21 billion.
Net income expanded 43% to $377 million.
EPS grew 45% to $4.26.
What management had to say
...
https://finance.yahoo.com/news/idexx-lab...19298.html
![[Bild: IDXXc1dl1725.png]](https://finviz.com/publish/020119/IDXXc1dl1725.png)
What happened with IDEXX Laboratories this quarter?
The companion animals business continues to be the star of the show. Sales in this division grew 10% on a reported basis.
Total instrument placements grew 8% to 3,957. The growth was led by its flagship Catalyst product, which posted instrument growth of 10%.
Recurring revenue from the companion animal group jumped 12%.
Reference laboratory diagnostic revenue grew 11% on an organic basis.
IDEXX's water business line grew 8% on an organic basis.
The company's livestock division declined 9% on a reported basis, but it grew 5% on an organic basis. Management said that African swine flu outbreaks in China were a major headwind for this business during the quarter.
Gross margin increased 90 basis points to 54.7%.
Operating margin expanded 170 basis points to 21%.
The huge jump in EPS is largely attributable to an elevated tax bill in the year-ago period. Adjusted EPS growth of 40% was still quite strong.
Zooming out to full-year results, here are the headline numbers for investors to see how the company did in 2018:
Revenue grew 12% to $2.21 billion.
Net income expanded 43% to $377 million.
EPS grew 45% to $4.26.
What management had to say
...
https://finance.yahoo.com/news/idexx-lab...19298.html